No connection

Search Results

AHG vs PAHC

AHG
Akso Health Group
BEARISH
Price
$2.50
Market Cap
$2.14B
Sector
Healthcare
AI Confidence
85%
PAHC
Phibro Animal Health Corporation
NEUTRAL
Price
$53.88
Market Cap
$2.18B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AHG
--
PAHC
23.84
Forward P/E
AHG
--
PAHC
15.9
P/B Ratio
AHG
10.82
PAHC
6.57
P/S Ratio
AHG
144.3
PAHC
1.49
EV/EBITDA
AHG
-4387.63
PAHC
12.6

Profitability

Gross Margin
AHG
1.0%
PAHC
32.3%
Operating Margin
AHG
-20.54%
PAHC
14.71%
Profit Margin
AHG
0.0%
PAHC
6.29%
ROE
AHG
-68.29%
PAHC
31.8%
ROA
AHG
-1.42%
PAHC
8.34%

Growth

Revenue Growth
AHG
0.9%
PAHC
20.9%
Earnings Growth
AHG
--
PAHC
752.0%

Financial Health

Debt/Equity
AHG
0.01
PAHC
2.33
Current Ratio
AHG
1.53
PAHC
3.05
Quick Ratio
AHG
1.19
PAHC
1.03

Dividends

Dividend Yield
AHG
--
PAHC
0.89%
Payout Ratio
AHG
0.0%
PAHC
21.24%

AI Verdict

AHG BEARISH

AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.

Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns
PAHC NEUTRAL

PAHC exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an impressive ROE of 31.80%, indicating efficient operational management. While the stock trades at a significant premium to its Graham Number ($20.42), it remains below its growth-based intrinsic value of $66.67. However, the bullish fundamental outlook is heavily countered by aggressive insider selling from the CEO and a very bearish technical trend (10/100). The company is in a high-growth phase with strong EPS beats, but the divergence between financial health and insider sentiment warrants a neutral stance.

Strengths
Strong Piotroski F-Score (7/9) indicating robust financial health
Exceptional Return on Equity (ROE) of 31.80%
Strong revenue growth (20.90% YoY) and consistent earnings beats
Risks
Aggressive insider selling, specifically concentrated in the CEO
High Debt/Equity ratio of 2.33
Severe bearish technical trend (10/100)

Compare Another Pair

AHG vs PAHC: Head-to-Head Comparison

This page compares Akso Health Group (AHG) and Phibro Animal Health Corporation (PAHC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile